If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein about 180-190 kDa. It is shown that CD109 is expressed in vascular endothelial cells, some epithelial cells, activated T-cells and platelets, and a subset of CD34+ megakaryocytic leukemia cells. CD109 molecules are strongly expressed in KG1a cells, while CD34+CD109+ cells in fetal bone marrow include almost all myelocytic, erythroblastic and megakaryocytic precursor cells. For this reason, CD109 is considered to be a marker of megakaryocytic hematopoiesis in the early stages. CD109 is considered different from existing activation markers of leukocytes and platelets because of its structure and serological features. According to a report by Takahashi et al., CD109 is significantly over expressed in squamous cell carcinoma such as lung carcinoma, esophageal carcinoma and uterine cervical carcinoma. Thus, it is attracting attention in study of squamous cell carcinoma. Description: Serum. Synonyms: Polyclonal CD109 antibody, Anti-CD109 antibody, Platelet-specific Gov antigen antibody, 150 kDa TGF-beta-1-binding protein antibody, PZP-like alpha-2-macroglobulin domain-containing protein antibody.
Immunogen
CD109 antibody was raised in rabbit using a synthetic peptide corresponding to part of Human CD109 as the immunogenSerum